We received the notification from Seegene, in which they confirmed the detectability of Allplex™ assays with respect to the Omicron variant, B.1.1.529 of SARS-CoV-2, which has emerged in South Africa.
- info@buhlmannlabs.ch
- +41 61 487 12 12
News
Interview with Dr. Cyril A. Fuhrer about the successful evaluation of the BÜHLMANN fPELA® turbo test at Synlab Suisse SA in Lucerne.
The guidelines on the diagnosis and treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were revised by a taskforce recently. They advise anti-MAG antibody testing by means of BÜHLMANN anti-MAG Autoantibodies ELISA in all patients with an IgM paraprotein fulfilling CIDP diagnostic criteria.
At the European Crohn’s and Colitis Organization (ECCO) 2021 congress Therapeutic Drug Monitoring (TDM) as well as remote monitoring were key topics with the ongoing pandemic forcing new ways of patient care. Of the presented abstracts, several stand out as they are using IBDoc® or BÜHLMANN’s Quantum Blue® TDM portfolio.
Social Links